CALZF Stock Chart & Stats
$0.73
-$0.78(-42.86%)
At close: 4:00 PM EST
$0.73
-$0.78(-42.86%)
Day’s Range― - ―
52-Week Range$0.55 - $1.03
Previous CloseN/A
Volume1.00K
Average Volume (3M)1.06K
Market Cap
$391.14M
Enterprise Value$847.73
Total Cash (Recent Filing)$29.26M
Total Debt (Recent Filing)$31.74M
Price to Earnings (P/E)60.8
Beta2.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding690,843,000
10 Day Avg. Volume2,300
30 Day Avg. Volume1,056
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$0.90Price Target Upside23.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginA 95.9% gross margin indicates strong unit economics from NovoSorb polymer products. Durable margin strength supports reinvestment in sales, clinical trials and manufacturing, provides a buffer versus pricing pressure and underpins long‑term profitability if maintained with scale.
Strong U.S. Commercial TractionConsistent double‑digit U.S. growth and expanding account base (>800 hospitals) reflect durable market penetration and repeat clinical adoption. Broadening contracted channels (GPO/IDM/federal) reduces single‑customer risk and supports predictable procedure‑driven revenue over the medium term.
Large Increase In Manufacturing CapacityA validated facility with ~5x prior capacity materially raises production scalability and lowers unit costs long term. It supports multi‑SKU supply, reduces previous capacity constraints, and enables geographic and outpatient expansion without immediate need for incremental capital.
Bears Say
Weak Free Cash Flow ConversionNegative FCF growth and very low operating cash conversion signal limited cash generated from profits. This constrains self‑funding for RCTs, reimbursement efforts and commercial expansion, increasing reliance on existing cash or external financing until conversion improves.
Outpatient Reimbursement UncertaintyOutpatient channel upside depends on CMS coding/reimbursement and likely requires an RCT to secure coverage. That adds multi‑quarter to multi‑year timing risk for a large addressable market, delaying predictable revenue and reducing near‑term earnings contribution from outpatient sales.
Lumpy Burn Market And Limited VisibilityDependence on irregular burn case volumes creates quarter‑to‑quarter revenue variability and limits forecasting accuracy. That operational unpredictability complicates capacity planning, inventory and go‑to‑market investment pacing, and reduces near‑term visibility for stakeholders.
Polynovo News
CALZF FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest stock price was $0.55 and its highest was $1.03 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is $391.14M.
When is Polynovo Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Polynovo Limited’s earnings last quarter?
Currently, no data Available
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in CALZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.90 (23.45% Upside)
$0.90 (23.45% Upside)
Blogger Sentiment
Bullish
CALZF Sentiment 95%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Polynovo Limited
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
CALZF Stock 12 Month Forecast
Average Price Target
$0.90
▲(23.45% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―
Ownership Overview
3.36% Insiders
2.70% Mutual Funds
― Other Institutional Investors
92.01% Public Companies and
Individual Investors